Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.62 |
| ▸ | CA2 | P00918 | 19/20 | 0.62 |
| ▸ | CA9 | Q16790 | 19/20 | 0.62 |
| ▸ | CA12 | O43570 | 17/20 | 0.62 |
| ▸ | CA7 | P43166 | 8/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 13/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872330 | 0.90 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL27669127 | 0.75 | CA1 (0.65) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21810947 | 0.74 | LMNA (0.61) | — | |
| SCHEMBL28457987 | 0.74 | CA1 (0.74) | CA1CA2CA9CA12CA7 | |
| SCHEMBL25339764 | 0.74 | LMNA (0.52) | TSHRCA4 | |
| SCHEMBL615392 | 0.73 | CA2 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL19891669 | 0.73 | CA12 (0.79) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9773543 | 0.73 | CA2 (0.74) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28005094 | 0.72 | CA1 (0.77) | CA1CA2CA9CA12CA7 | |
| SCHEMBL7450680 | 0.72 | CA12 (0.67) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319170-B2 | N-cyclohexylaminocarbonyl benzensulfonmide derivatives | MERCK & CO., INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20060111585-A1 | Title of the invention n-cyclohexylaminocarbonyl benzensulfonmide derivatives | MERCK SHARP & DOHME CORP. | 2006-05-25 | — | — | US | disclosed |
| EP-1587535-A2 | TITLE OF THE INVENTION N-CYCLOHEXYLAMINOCARBONYL BENZENESULFONAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004066963-A2 | N-CYCLOHEXYLAMINOCARBONYL BENZENESULFONAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111585-A1 | Title of the invention n-cyclohexylaminocarbonyl benzensulfonmide derivatives | PPARD, PPARA, PPARG | CA1 4831/4885CA2 2215/4885CA9 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.